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Abbreviations 32 
AMI : Acute myocardial infarction  33 
CAD : Coronary artery disease 34 
CK : Creatine Kinase 35 
cTn : Cardiac troponin 36 
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Cardiac troponin (cTn) T and I are regarded equivalent in the diagnosis of acute myocardial 38 
infarction (AMI)(1), as they correlate closely with each other and show very high and 39 
comparable diagnostic accuracies.(2) In contrast, isolated high concentrations of cTnT, but not 40 
cTnI, have been reported in patients with chronic hereditary and acquired skeletal 41 
myopathies.(3, 4) The reported strong positive correlation between creatine kinase (CK), a 42 
quantitative marker of muscle injury, and high-sensitivity (hs)-cTnT (r=0.679, p<0.001) 43 
indicated either re-expression of cTnT in diseased skeletal muscle or cross-reactivity of the 44 
cTnT assay with circulating muscle epitopes as possible explanations.(4) To advance the 45 
understanding of the involved mechanisms, we aimed to investigate high-sensitivity assays for 46 
hs-cTnT (Elecsys, Roche) and hs-cTnI (Architect, Abbott) in patients with acute 47 
rhabdomyolysis, an in-vivo model of massive acute skeletal muscle protein release into the 48 
circulation, and compare their inter-assay association with matched acute chest pain patients 49 
presenting with non-coronary chest pain to the emergency department.   50 
In a prospective observational study, approved by the ethical committee, we measured CK, hs-51 
cTnT, and hs-cTnI in 98 consecutive patients presenting with acute rhabdomyolysis (defined 52 
as CK>7500U/L) resulting in 268 parallel measurements. Mean age was 62 years, 22% were 53 
female, history of coronary artery disease (CAD) was present in 14%, hypertension in 38%, 54 
ECG abnormalities in 20% (ECG available in 68/98) and echocardiographic abnormalities in 55 
12% (Echocardiography available in 38/98). Acute medical illnesses was the cause in 93/98, 56 
thoracic trauma or cardiopulmonary reanimation in 5/98. 57 
Log-transformed hs-cTnT (r=-0.14, p=0.025) and hs-cTnI (r=-0.16, p=0.008) showed a weak 58 
and negative correlation with CK concentrations (Figure 1A), indicating no meaningful 59 
association between the extent of skeletal muscle injury and hs-cTnT and hs-cTnI 60 
concentrations. 61 
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Propensity score matching with well-characterized patients adjudicated to have non-coronary 62 
chest pain in the Advantageous Predictors of Acute Coronary Syndrome Evaluation study 63 
(NCT00470587) on age, sex, history of hypertension, CAD, AMI, stroke, and chronic skeletal 64 
muscle disease was performed to assess whether hs-cTnT and hs-cTnI concentrations behave 65 
disproportionally different in patients with rhabdomyolysis than in the matched controls. 66 
Following matching, cardiovascular comorbidities were equalized, while patients with acute 67 
rhabdomyolysis had more extensive systemic inflammation as quantified by C-reactive protein 68 
concentrations and worse renal function as compared to the matched control cohort. 69 
Hs-cTnT and hs-cTnI concentrations measured in the same blood sample (Figure 1B) showed 70 
a strong positive correlation in both cohorts (Pearson coefficient 0.91 in control and of 0.93 in 71 
rhabdomyolysis, both p<0.001) and behaved comparably in the control and the rhabdomyolysis 72 
cohort, as confirmed by similar slopes of fitted regression lines (log(hs-cTnT)= 0.62*log(hs-73 
cTnI)) in the controls and log(hs-cTnT)= 0.59*log(hs-cTnI) in the rhabdomyolysis patients). A 74 
linear model including the interaction of the presence of rhabdomyolysis showed no significant 75 
interaction due to the presence of rhabdomyolysis (p-for-interaction=0.14). Hs-cTnT and hs-76 
cTnI concentrations were both higher in the rhabdomyolysis patients as compared to controls 77 
(median hs-cTnT 22.0ng/L versus 14.9ng/L; median hs-cTnI 21.5ng/L versus 8.6ng/L, 78 
p<0.001, respectively).  79 
Three important insights of major clinical relevance evolved from these analyses. First, acutely 80 
diseased skeletal muscle as in rhabdomyolysis does not seem to be a relevant source of hs-cTnT 81 
concentrations in the circulation. Second, cardiomyocyte injury due to the underlying acute 82 
medical disease leading to rhabdomyolysis such as severe sepsis, stroke or even asymptomatic 83 
AMI is the most likely source of cTnT and cTnI concentrations in patients with rhabdomyolysis 84 
and responsible for the higher concentrations of cTnT/cTnI than the matched controls.(1) 85 
Further research with systematic cardiac imaging in rhabdomyolysis patients is warranted. 86 
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Third, massive acute release of skeletal muscle epitopes in the circulation as in acute 87 
rhabdomyolysis does not lead to disproportionally increased hs-cTnT concentrations, but 88 
modest release as in chronic hereditary and acquired skeletal myopathies seems to.(3, 4) Time-89 
dependent re-expression of cTnT in chronically diseased skeletal muscle may be considered the 90 




Figure 1 – Logged High-sensitivity cardiac troponin T (hs-cTnT) concentrations show A) a 95 
weak negative correlation with creatine kinase (CK), but B) a strong and positive correlation 96 
with logged hs-cTnI concentrations in rhabdomyolysis (red), with linear regression slopes 97 
comparable to those in matched controls (blue). Dashed lines : Medians for both cohorts.  98 
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